Amphastar Pharmaceuticals (AMPH) reported $720M in revenue for fiscal 2025, −1.7% year on year. That ranks #1993 by revenue among 2853 SEC filers and #189 in Healthcare. Net income was $98.1M, a net margin of 13.6%. Revenue has grown 12.2% a year on average since 2016 ($255M then). The fiscal 2025 balance sheet shows $1.6B in total assets, $170M in cash and $620M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenues | $720M | −1.7% | FY20252025-12-31 |
| Gross profitGrossProfit | $356M | −4.8% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | $140M | −31.7% | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $98.1M | −38.5% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $156M | −26.8% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $34.9M | −15.0% | FY20252025-12-31 |
| Total assetsAssets | $1.6B | +3.3% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest | $789M | +7.7% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $170M | +12.2% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $620M | +1.0% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $171M | $6.4M | Open → |
| Q2 20262026-06-30 | $184M | $30.3M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Amphastar Pharmaceuticals, Inc.
- Ticker
- AMPH
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0001297184
Filings
- 10-QAug 6, 2026Open filing →
- 10-QMay 7, 2026Open filing →
- 10-KFeb 26, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Emergent BiosolutionsEBS | $743M | $52.6M |
| RepligenRGEN | $738M | $48.9M |
| Pacira BiosciencesPCRX | $726M | $7.0M |
| Amphastar PharmaceuticalsAMPH | $720M | $98.1M |
| Supernus PharmaceuticalsSUPN | $719M | −$38.6M |
| Avanos MedicalAVNS | $701M | −$72.9M |
| Kiniksa Pharmaceuticals InternationalKNSA | $678M | $59.0M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Amphastar Pharmaceuticals — Key figures |url=https://companiesranked.com/en/company/amphastar-pharmaceuticals |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Amphastar Pharmaceuticals — Key figures. CompaniesRanked. https://companiesranked.com/en/company/amphastar-pharmaceuticalsBibTeX
@misc{companiesranked-en-company-amphastar-pharmaceuticals-2026,
author = {{CompaniesRanked}},
title = {{Amphastar Pharmaceuticals — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/amphastar-pharmaceuticals}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001297184-26-000009 · February 26, 2026
{{cite web |title=Amphastar Pharmaceuticals — Key figures — 10-K (0001297184-26-000009) |url=https://www.sec.gov/Archives/edgar/data/1297184/000129718426000009/amph-20251231x10k.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-26}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.